CMS Adds Gold Standard’s Clinical Pharmacology to List of Medicare Anti-Cancer Treatment Compendia
Gold Standard's focus on quality and accuracy was recognized by two research studies
Tampa, FL - July 2, 2008 - The Centers for Medicare & Medicaid Services (CMS) has added Clinical Pharmacology, the award-winning drug information and medication management reference from Gold Standard, an Elsevier company, to its list of Medicare anti-cancer treatment compendia used in determining which drugs may be covered under Medicare Part B to treat patients undergoing cancer treatment through chemotherapy.
“The decision by CMS to add Clinical Pharmacology as an official drug compendium for use in determining appropriate drugs and biologics for use in oncology is validation of the quality of Gold Standard’s evidence-based drug content,” said Kathleen Vieson, PharmD, BCOP, Gold Standard Vice President and Director of Clinical References.
The decision, which was announced by CMS in a press release, was made following a rigorous evaluation based on criteria established by CMS’ Medicare Evidence Development & Coverage Advisory Committee. Criteria included a transparent process for evaluating therapies and for public identification and notification of potential conflicts of interest of the compendia’s parent and sibling organizations, reviewers and committee members. CMS’ compendia-revising process also included a 30-day public comment period.
In its final decision, CMS notes that all comments received supported Clinical Pharmacology’s addition and “attributed the usefulness of the Clinical Pharmacology compendium for off-label use to its broad accessibility, timeliness and user-friendly format. Commenters also noted although they view this compendium as a vital clinical resource, formal recognition of the Clinical Pharmacology would allow it to be an authoritative resource for Medicare coverage determinations.”
“To ensure the integrity of Clinical Pharmacology’s content, our editorial team has established a hierarchy of data evaluation that gives preference to publications that embrace the peer-review methodology,” said MaryAnne Hochadel, PharmD, BCPS, Gold Standard Vice President and Editor-in-Chief. “Drug and medical data is integrated from multiple, credible resources and distilled down into concise, actionable information. It is also continuously updated in real-time to ensure the information in Clinical Pharmacology is both current and accurate.”
Gold Standard’s focus on ensuring the quality and accuracy of Clinical Pharmacology’s content was recognized by two independent research studies, which found it to be superior to its competition.
In “Comparison of Tertiary Drug Information Databases” by Butler University College of Pharmacy and Health Sciences, Clinical Pharmacology scored highest among the tertiary online drug information databases for clinical dependability and completeness. In “Evaluation of the Functionality of Subscription and Free Online Drug Information Databases” by Nova Southeastern University College of Pharmacy, it outranked the competition by achieving the highest overall composite score which integrated scope, completeness and ease of use.
A compendium is a listing of U.S. Food and Drug Administration (FDA) - approved drugs and biologics that includes a summary of how each drug works in the body, as well as information for healthcare practitioners about proper dosing and whether the drug is recommended or endorsed for use in treating a specific disease. In some cases, compendia specialize in a particular subset of drugs, such as those used for cancer treatment.
Medicare local contractors, which process and pay Medicare claims and approve coverage for drugs under Medicare Part B, use compendia as one of several tools to determine whether an anti-cancer drug may be covered under Medicare Part B.
# # #
About Gold Standard
Based in Tampa, Fla., Gold Standard is a leading developer of drug information databases, software and clinical information solutions. The Company’s products are developed by a staff of highly trained professionals with extensive experience in pharmacy practice, electronic publishing and software development. Customers include more than 1,000 hospitals, the nation’s largest retail pharmacy chains and consultant pharmacy organizations, state and federal agencies, the country’s top pharmacy and medical schools, leading health information websites, and hundreds of thousands of healthcare professionals and consumers worldwide. Gold Standard’s parent company, Elsevier, is a world-leading publisher of scientific, technical and medical information products and services with more than 7,000 employees in over 70 offices across 24 countries. To learn more about Gold Standard, visit www.goldstandard.com or call +1 (800) 375-0943.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).